Y Xie1,2,3, C Li3, L Zhang1, S Zang1, F Yu1, S Wang2, F Wang1. 1. Department of Nuclear Medicine, Nanjing First Hospital, Nanjing Medical University, Nanjing 210006, China. 2. Department of Laboratory Medicine, Nanjing First Hospital, Nanjing Medical University, Nanjing 210006, China. 3. Department of Nuclear Medicine, Zhongda Hospital, Southeast University, Nanjing 210009, China.
Abstract
OBJECTIVE: To investigate the value of 68Ga-labeled prostate specific membrane antigen (PSMA) PET/CT for assessing tumor load in primary lesions for risk stratification and predicting metastasis of newly diagnosed prostate cancer (PCa). METHODS: We retrospectively analyzed the data of 36 patients (mean age 71.3 ± 8.6 years, range 56 to 89 years) with newly diagnosed PCa undergoing 68Ga-PSMA-I&T PET/CT from June 2018 to July 2019. SUVmax and SUVmean of the primary lesions were measured, and the primary PSMA tumor volume (PSMA-TV) and total lesion PSMA (TL-PSMA) were automatically measured and calculated in all the patients. The correlations of primary SUVmax, PSMA-TV, and TL-PSMA with PSA and Gleason score (GS) were analyzed, and SUVmax, PSMA-TV and TL-PSMA of the primary lesions were compared among different PCa subgroups. RESULTS: SUVmax, PSMA-TV and TL-PSMA of the primary lesions were all correlated with PSA and GS (P < 0.05). PCa subgroup analysis showed that SUVmax, PSMA-TV and TL-PSMA were all significantly higher in patients with PSA >20 ng/mL than in those with PSA ≤20 ng/mL (P < 0.001), and were higher in patients with a GS ≥8 than in those with a GS ≤7 (P < 0.001). PSMA-TV and TL-PSMA were significantly higher in patients with tumor metastasis than in those without metastasis (P < 0.001), while SUVmax did not differ significantly with tumor metastasis. SUVmax (P=0.002), PSMA-TV (P < 0.001), and TL-PSMA (P < 0.001) were all significantly higher in high-risk group than in low-to moderate-risk group. CONCLUSION: PSMA-TV and TL-PSMA of 68Ga-PSMA-I&T PET/CT have potential value in predicting risk stratification and metastasis of newly diagnosed PCa.
OBJECTIVE: To investigate the value of 68Ga-labeled prostate specific membrane antigen (PSMA) PET/CT for assessing tumor load in primary lesions for risk stratification and predicting metastasis of newly diagnosed prostate cancer (PCa). METHODS: We retrospectively analyzed the data of 36 patients (mean age 71.3 ± 8.6 years, range 56 to 89 years) with newly diagnosed PCa undergoing 68Ga-PSMA-I&T PET/CT from June 2018 to July 2019. SUVmax and SUVmean of the primary lesions were measured, and the primary PSMA tumor volume (PSMA-TV) and total lesion PSMA (TL-PSMA) were automatically measured and calculated in all the patients. The correlations of primary SUVmax, PSMA-TV, and TL-PSMA with PSA and Gleason score (GS) were analyzed, and SUVmax, PSMA-TV and TL-PSMA of the primary lesions were compared among different PCa subgroups. RESULTS: SUVmax, PSMA-TV and TL-PSMA of the primary lesions were all correlated with PSA and GS (P < 0.05). PCa subgroup analysis showed that SUVmax, PSMA-TV and TL-PSMA were all significantly higher in patients with PSA >20 ng/mL than in those with PSA ≤20 ng/mL (P < 0.001), and were higher in patients with a GS ≥8 than in those with a GS ≤7 (P < 0.001). PSMA-TV and TL-PSMA were significantly higher in patients with tumor metastasis than in those without metastasis (P < 0.001), while SUVmax did not differ significantly with tumor metastasis. SUVmax (P=0.002), PSMA-TV (P < 0.001), and TL-PSMA (P < 0.001) were all significantly higher in high-risk group than in low-to moderate-risk group. CONCLUSION: PSMA-TV and TL-PSMA of 68Ga-PSMA-I&T PET/CT have potential value in predicting risk stratification and metastasis of newly diagnosed PCa.
Authors: Stefan A Koerber; Maximilian T Utzinger; Clemens Kratochwil; Claudia Kesch; Matthias F Haefner; Sonja Katayama; Walter Mier; Andrei H Iagaru; Klaus Herfarth; Uwe Haberkorn; Juergen Debus; Frederik L Giesel Journal: J Nucl Med Date: 2017-06-15 Impact factor: 10.057
Authors: Thorsten Derlin; Desiree Weiberg; Christoph von Klot; Hans-Jürgen Wester; Christoph Henkenberens; Tobias L Ross; Hans Christiansen; Axel S Merseburger; Frank M Bengel Journal: Eur Radiol Date: 2016-03-24 Impact factor: 5.315
Authors: Danielle P Meyrick; Marcus Asokendaran; Laura A Skelly; Nat P Lenzo; Andrew Henderson Journal: Nucl Med Commun Date: 2017-11 Impact factor: 1.690
Authors: Seong Yong Park; Arthur Cho; Woo Sik Yu; Chang Young Lee; Jin Gu Lee; Dae Joon Kim; Kyung Young Chung Journal: J Nucl Med Date: 2014-12-18 Impact factor: 10.057
Authors: Sebastian Schmuck; Martin Mamach; Florian Wilke; Christoph A von Klot; Christoph Henkenberens; James T Thackeray; Jan M Sohns; Lilli Geworski; Tobias L Ross; Hans-Juergen Wester; Hans Christiansen; Frank M Bengel; Thorsten Derlin Journal: Clin Nucl Med Date: 2017-06 Impact factor: 7.794
Authors: Chen Liu; Teli Liu; Ning Zhang; Yiqiang Liu; Nan Li; Peng Du; Yong Yang; Ming Liu; Kan Gong; Xing Yang; Hua Zhu; Kun Yan; Zhi Yang Journal: Eur J Nucl Med Mol Imaging Date: 2018-05-02 Impact factor: 9.236
Authors: Martina Wirtz; Alexander Schmidt; Margret Schottelius; Stephanie Robu; Thomas Günther; Markus Schwaiger; Hans-Jürgen Wester Journal: EJNMMI Res Date: 2018-08-22 Impact factor: 3.138